Scarica l'app Stockscreener
70.21
0.54%
0.38
Dopo l'orario di chiusura:
70.21
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Disc Medicine Inc Borsa (IRON) Ultime notizie
Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), ... - Caledonian Record
Disc Medicine Investor News: If You Have Suffered Losses in - GlobeNewswire
Disc Medicine (IRON) Study update Summary - Quartr
Disc Medicine, Inc. (IRON) Discusses Clinical Updates on Bitopertin, Selcodebart, and DISC-3405 and Strategic OutlookSlideshow (NASDAQ:IRON) 2026-06-15 - Seeking Alpha
IRON: Bitopertin and selcodebart show strong efficacy in EPP and MF anemia, with pivotal data due Q4 2026 - TradingView
IRON: Durable anemia responses and improved outcomes seen in Phase 2 trials for DISC-0974 and bitopertin - TradingView
Disc Medicine, Inc. $IRON Shares Sold by First Turn Management LLC - MarketBeat
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - The Berkshire Eagle
NEXTBio Capital Management LP Takes $3.40 Million Position in Disc Medicine, Inc. $IRON - MarketBeat
Nicholas Investment Partners LP Sells 39,921 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine, Inc. $IRON Stock Position Lowered by Frazier Life Sciences Management L.P. - MarketBeat
Disc Medicine, Inc. $IRON Shares Sold by Atlas Venture Life Science Advisors LLC - MarketBeat
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Disc Medicine reports positive data for hematology pipeline at EHA 2026 - grafa.com
Disc Medicine presents trial data for blood disorder treatments - Investing.com
Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting - The Manila Times
Disc Medicine Announces Promising RALLY-MF and HELIOS Trial Data at EHA Annual Meeting - Quiver Quantitative
Anemia and light-tolerance gains seen in Disc Medicine studies - Stock Titan
Disc Medicine (IRON) Is Down 8.6% After Mixed Trial Success And FDA Setback What's Changed - Sahm
IRON Reiterated by Wedbush -- Price Target Maintained at $88.00 - GuruFocus
Wedbush Reiterates Outperform Rating for Disc Medicine (NASDAQ:IRON) - MarketBeat
Wedbush Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $88 - Moomoo
IRON Investor News: If You Have Suffered Losses in Disc - GlobeNewswire
LifeSci Capital Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Disc Medicine aligns with FDA on path for bitopertin approval By Investing.com - Investing.com Australia
Disc Medicine, FDA agree on approval path for rare disease drug - Seeking Alpha
Disc Medicine aligns with FDA on path for bitopertin approval - Investing.com
Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria - The Manila Times
Bitopertin EPP trial measures pain-free time in sunlight - Stock Titan
BNP Paribas Financial Markets Has $9.70 Million Stock Position in Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine Stock Slumps After FDA Declines Approval For Inherited Disorder Drug Over Efficacy Concerns - Stocktwits
Assessing Disc Medicine (IRON) Valuation After New Trial Data And Expanded Access Program News - Sahm
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - ACCESS Newswire
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are ... - Caledonian Record
Liquidity Mapping Around (IRON) Price Events - Stock Traders Daily
Diamond Blackfan Anemia Market Unlocking New Revenue - openPR.com
Medpace Deadline: MEDP Investors with Losses in Excess of $100K Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit - PR Newswire
BRTX: Advancing late-stage cell therapies for spine, metabolic, and aesthetic markets with strong IP - TradingView
IRON: Bitopertin advances toward pivotal data and regulatory milestones, targeting broad anemia indications - TradingView
Program provides early access to experimental EPP treatment - Porphyria News
Truist Financial Maintains Disc Medicine(IRON.US) With Buy Rating - Moomoo
A Quick Look at Today's Ratings for Disc Medicine(IRON.US), With a Forecast Between $100 to $118 - Moomoo
Stifel reiterates Disc Medicine stock rating on anemia trial data By Investing.com - Investing.com South Africa
Stifel reiterates Disc Medicine stock rating on anemia trial data - Investing.com
Disc Medicine (IRON) Reports Promising Results from RALLY-MF Pha - GuruFocus
Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
Experimental anemia drug cuts transfusions in myelofibrosis trial - Stock Titan
How Investors May Respond To Disc Medicine (IRON) Expanding Pre-Approval Access To Bitopertin For Porphyria Patients - Yahoo Finance
Disc Medicine Launches Expanded Access Program for Bitopertin for Epp Patients - marketscreener.com
Disc Medicine launches expanded access program for bitopertin By Investing.com - Investing.com South Africa
Disc Medicine launches expanded access program for bitopertin - Investing.com
Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients - The Manila Times
Disc program offers EPP patients bitopertin before FDA decision - Stock Titan
IRON Technical Analysis & Stock Price Forecast - Intellectia AI
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):